Navigation Links
SynCo Bio Partners Increases its Capacities by Expanding its Quality Team
Date:7/20/2009

AMSTERDAM, July 20 /PRNewswire/ -- SynCo Bio Partners B.V., the GMP contract manufacturer of biological-based vaccines and therapeutics, today announced that it had significantly expanded the number of clinical and commercial biopharmaceutical batches it is capable of releasing annually, whilst improving regulatory support continuity for its clients, with the addition of a second Qualified Person (QP) to its Quality Affairs team: Raoul Fisser

Raoul joined SynCo's Quality Affairs team from Astellas Pharma where he worked in Pharmaceutical Development, having previously gained experience in the Quality Assurance Department of the largest manufacturing site of Yamanouchi in Japan. He will now support SynCo's existing QP Rob Sprenkels, in the release of GMP batches of recombinant protein, polysaccharide and live-microbial-based bulk drug substances and final product. This addition reflects SynCo's growing client base and the solid business it has established.

'Raoul is an excellent addition to SynCo's Quality Affairs team and this expansion demonstrates the continuous growth in both client base and batch production at SynCo since our inception in 2000. Going forward, we look to supporting our clients in GMP production of an even wider range of novel biopharmaceuticals.' commented Pierre Warffemius, CEO of SynCo Bio Partners.

SynCo's expansion in batch release capabilities is a positive step in an ever increasingly competitive CMO market and is of special significance in the current global economic downturn. This development will allow SynCo to continue to grow revenues and to increase the number of GMP biopharmaceutical batches it can release each year.

For more information, please visit http://www.syncobiopartners.com

About SynCo Bio Partners B.V.

SynCo Bio Partners is a GMP-licensed bulk drug substance and final product CMO with clinical and commercial production experience with mammalian and microbial systems. This experience has been acquired by developing new production processes for a number of international clients and producing a wide variety of different vaccines, live bacterial products and recombinant proteins in our state-of-the-art, GMP-licensed facilities since inception in 2000.

Focused solely on biopharmaceuticals, SynCo Bio Partners acts as a strategic, long-term partner delivering product on time to the highest quality standards. SynCo 's team are committed to exceeding customer expectations taking a truly collaborative approach to manufacturing.

http://www.syncobiopartners.com


'/>"/>
SOURCE SynCo Bio Partners B.V.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. SynCo Bio Partners Wins Best Contract Manufacturing Organization 2009 ViE Award
2. SynCo Bio Partners Completes Manufacture and Release of ActoGeniX Lead Product for Phase II Clinical Trials
3. Champions Biotechnology Partners with Do-Coop Technologies to Advance Its Novel Oncology Compound Into Biomerk Tumorgraft(TM) Testing
4. Thomson Reuters Partners With Sagient Research
5. TransTech Services Partners, Inc. Shareholders Approve Plan of Liquidation; Company To Distribute Amounts in Trust
6. Essilor: Essilor Forges New Strategic Partnerships Around the World
7. ACT Announces Partnership With Gilead Sciences Inc.
8. New Leadership Team at International Trachoma Initiative to Build Stronger Partnerships to Eliminate Blinding Trachoma
9. Air Force Chief Master Sergeant Rod McKinley (U.S. Air Force Retired) Joins MicroTech as Vice President of Strategic Partnerships
10. MIT is pleased to announce that it has received a US$ 500,000 private placement from its Chinese partners
11. Galichia Heart Hospital Partners with Mobile Surgery International to Develop Wichita-based Center of Excellence with Global Convenience(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... 27, 2016 , ... Rolf K. Hoffmann, former senior vice ... University of North Carolina Kenan-Flagler Business School effective June 27. , ... with a focus on the school’s international efforts, leading classes and participating in ...
(Date:6/24/2016)... , June 24, 2016  Regular discussions on a ... take place between the two entities said Poloz. ... Ottawa , he pointed to the country,s ... the federal government. ... said, "Both institutions have common economic goals, why not sit ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Researchers at ... most commonly-identified miRNAs in people with peritoneal or pleural mesothelioma. Their findings are the ... read it now. , Diagnostic biomarkers are signposts in the blood, lung fluid ...
(Date:6/23/2016)... , June 23, 2016   Boston ... of novel compounds designed to target cancer stemness ... has been granted Orphan Drug Designation from the ... treatment of gastric cancer, including gastroesophageal junction (GEJ) ... inhibitor designed to inhibit cancer stemness pathways by ...
Breaking Biology Technology:
(Date:5/20/2016)... MINNEAPOLIS , May 20, 2016  VoiceIt ... technology partnership with VoicePass. By working ... user experience.  Because VoiceIt and VoicePass take slightly ... two engines increases both security and usability. ... expressed excitement about this new partnership. ...
(Date:5/9/2016)... , UAE, May 9, 2016 ... when it comes to expanding freedom for high net ... Even in today,s globally connected world, there is ... conferencing system could ever duplicate sealing your deal with ... obtaining second passports by taking advantage of citizenship via ...
(Date:4/28/2016)... , April 28, 2016 First quarter 2016: ... up 966% compared with the first quarter of 2015 ... SEK 589.1 M (loss: 18.8) and the operating margin was 40% ... 0.32) Cash flow from operations was SEK 249.9 M ... revenue guidance is unchanged, SEK 7,000-8,500 M. The operating ...
Breaking Biology News(10 mins):